


Vimseltinib

Cat. No.:	HY-136256		
CAS No.:	1628606-05-2		
Molecular Formula:	C ₂₃ H ₂₅ N ₇ O ₂		
Molecular Weight:	431.49		
Target:	c-Fms; c-Kit		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (115.88 mM; ultrasonic and warming and heat to 60°C)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.3176 mL	11.5878 mL	23.1755 mL
		5 mM	0.4635 mL	2.3176 mL	4.6351 mL
10 mM		0.2318 mL	1.1588 mL	2.3176 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3.5 mg/mL (8.11 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 3.5 mg/mL (8.11 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3.5 mg/mL (8.11 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC ₅₀ s of <0.01 μM and 0.1-1 μM, respectively ^[1] .
IC ₅₀ & Target	IC ₅₀ : <0.01 μM (c-FMS/CSF-IR), 0.1-1 μM (c-Kit) ^[1]
In Vitro	Vimseltinib is a c-FMS (CSF-IR) and c-Kit dual inhibitor with anti-cancer and anti-proliferative activities ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Yumi Ahn, et al. 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145025A2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA